Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases
NCT: NCT05829291 · RECRUITING
Brief Summary
This is a single center study enrolling up to 10 patients. The primary objective is to Evaluate the feasibility and safety of the DaRT for the treatment of Liver Metastases. The secondary objective is to evaluate the pathological response of liver metastases according to the Modified tumor regression grade\[1\] and to evaluate the radiological response of liver metastases using the RECIST criteria.
Frequently Asked Questions
What is Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases?
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases is a clinical trial registered under NCT05829291. Current status: RECRUITING.
What is the status of NCT05829291?
The current status of NCT05829291 (Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases) is: RECRUITING.
When did Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases start?
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases started on 2023-10-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.